Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.51 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851659 | 0.87 | TBXAS1 (0.56) | TBXAS1FFAR1 | |
| SCHEMBL7552548 | 0.85 | TBXAS1 (0.64) | TBXAS1 | |
| SCHEMBL27412442 | 0.84 | TBXAS1 (0.65) | TBXAS1 | |
| SCHEMBL17983732 | 0.80 | CAPN1 (0.46) | TBXAS1HCAR2 | |
| SCHEMBL4906214 | 0.80 | ALDH1A1 (0.52) | TBXAS1HCAR2 | |
| Hydrochloric Acid SCHEMBL10770836 | 0.78 | ALDH1A1 (0.50) | TBXAS1HCAR2 | |
| SCHEMBL21576889 | 0.77 | IAPP (0.49) | TBXAS1HCAR2 | |
| SCHEMBL1227049 | 0.76 | NAPRT (0.57) | P4HTMFFAR1HCAR2 | |
| SCHEMBL18381320 | 0.75 | SMN1; SMN2 (0.55) | — | |
| SCHEMBL29403620 | 0.75 | TBXAS1 (0.78) | KEAP1TBXAS1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220340535-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | HICKEY DEIRDRE MARY BERNADETTE (GB) | 2002-08-29 | — | — | US | disclosed |
| CN-1085980-C | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 2002-06-05 | — | — | CN | disclosed |
| EP-1175409-A1 | PYRIMIDINONES DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-30 | — | — | EP | disclosed |
| EP-1173424-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000068208-A1 | PYRIMIDINONES DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000066566-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-09 | — | — | WO | disclosed |
| EP-1028955-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SmithKline Beecham p.l.c. (GB) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024420-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1999-05-20 | — | — | WO | disclosed |
| CN-1201454-A | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 1998-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | PLA2G7, PLA2G1B, PLA2G4C | KEAP1 1760/4885TBXAS1 28/4885P4HTM 1795/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | KEAP1 153/4885TBXAS1 3051/4885P4HTM 3311/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | KEAP1 3929/4885TBXAS1 3983/4885P4HTM 2653/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | KEAP1 153/4885TBXAS1 3051/4885P4HTM 3311/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | KEAP1 2324/4885TBXAS1 4777/4885P4HTM 1825/4885 |
| US-20220340535-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | KEAP1 153/4885TBXAS1 3051/4885P4HTM 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.